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Introduction: Behçet’s disease (BD) as systemic vasculitis of unknown etiology is associated with HLA-B*51 in
European and Asian populations. HLA-A*26 was claimed as an additional BD susceptibility marker in Japanese and
Greek patients. This study was performed to test for HLA associations in HLA-B*51 negative German and Turkish BD
populations.
Methods: In total, 65 German and 46 Turkish patients lacking HLA-B*51 were analyzed in comparison to healthy HLA-B*51
negative Germans (n = 1500) and Turks (n = 130). HLA-A/B genotypes were determined by SSOP. P-values with
correction for multiple testing (pc), χ2-test and odds ratio (OR) were used for statistical evaluation.
Results: HLA-A*26 was significantly more frequent in HLA-B*51− German patients [pc = 0.0076, OR = 3.23, 95% CI
1.63 to 6.39] than in respective controls. HLA-A*26 was also elevated in a smaller group of Turkish patients versus
the controls. Significant association of HLA-Bw4 with isoleucine at amino-acid position 80 (HLA-Bw4-80I) was found
in the HLA-B*51− German cohort of BD patients [pc = 0.0042, OR = 2.35, 95% CI 1.41 to 3.93) and in the Turkish
patients in comparison to the respective controls [p = 0.025, OR = 2.17, 95% CI 1.09 to 4.31]. On the contrary,
HLA-Bw4-80 T was reduced in both HLA-B*51− BD patient cohorts.
Conclusions: The study shows a significant association of HLA-Bw4-80I present on HLA-B*51 as well as on other
B-locus molecules with BD. This indicates that distinctive Bw4 epitopes on HLA-B locus molecules could play a role
in BD pathogenesis. The study also indicates an association with HLA-A*26 in German and Turkish BD patients as a
genetic risk factor independent of HLA-B*51.Introduction
Behçet’s disease (BD) is a chronic relapsing multisystem
disorder of still unknown etiology with histopathologic
features of a leucocytoclastic vasculitis. It frequently ma-
nifests with recurrent oral and genital aphthosis, ocular in-
volvement, skin inflammation, and arthritis, but also can
affect many other organs. As a pathognomonic test for BD
is still lacking, International Criteria for BD (ICBD) [1]
based on characteristic clinical symptoms have been devel-
oped for standardized diagnosis. BD today occurs through-
out the world, but was classically only seen with a high
prevalence in countries along the old Silk routes leading* Correspondence: iskander.kuranov@gmail.com
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unless otherwise stated.from the Mediterranean via the Middle East to Japan. In
the native German population, BD is diagnosed as a rare
disease with an estimated prevalence of 0.6 cases per
100,000 inhabitants [2,3] and clinical manifestations simi-
lar to other ethnic groups.
An increased risk of BD has been noted in siblings of
BD patients for a long time and interpreted as a sign of
genetic susceptibility. In 1978, Ohno et al. [4] first de-
scribed the human leucocyte antigen gene (HLA)-B*51
(B*51) as a major genetic risk factor for BD, which was
subsequently confirmed in many other ethnic popula-
tions tested with odds ratios (ORs) up to 5.78 [5]. Up to
now it is still unknown, whether HLA-B*51 as a mol-
ecule itself or other linked genes within the HLA system
primarily contribute to BD susceptibility [6]. Many asso-
ciation studies of BD in different ethnic groups have
shown that only 60 to 75% of the cases carry HLA-B*51.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients are at least HLA-B*51-negative [7]. These observa-
tions suggest additional BD susceptibility genes. Recently,
advanced molecular linkage studies proposed MICA and/
or HLA-A*26:01 as genetic risk factors independent of
HLA-B*51, particularly in Japanese [8], Taiwanese [9] and
Greek [10] BD patients. Further analyses suggested that
other HLA molecules, particularly of the HLA-B locus,
might also be associated with BD [11]. Recent advances
in sequencing technology and genome-wide analyses pro-
vided more evidence for additional genetic associations
between BD and multiple single nucleotide polymorphism
(SNP) variants within the HLA-system. This pertains to
PSORS1C1 polymorphism, variants upstream of HLA-F-
AS1 and to HLA-C*16:02 [12]. Different loci outside of
the major histocompatability complex (MHC), such as IL-
10, IL-23R, CCR1, STAT4, MEFV, toll-like receptor (TLR)
4, which regulate inflammation or are involved in innate
immunity, have been also claimed to be linked to BD [13].
Furthermore, recent reports about an association of BD
with ERAP1 and KLRC4 implicated altered peptide-MHC
class I interactions with natural killer (NK) cell receptors
which could influence NK-cell activity in the pathogenesis
of the disease [11].
This study was performed to validate and test for HLA-
A and further HLA-B associations in German BD patients
as well as in a cohort of Turkish patients with long-
standing German residency. Both BD patient groups and
the respective healthy control groups were stratified ac-
cording to their lack of an HLA-B*51 phenotype. HLA-
B*51-negative BD patients were compared with respective




German (n = 65) and Turkish (n = 46) unrelated BD pa-
tients, who presented themselves at the outpatient clinic
of the University Hospital of Tübingen (Germany) dur-
ing the previous five years, were included in this study.
The patients were selected from a larger group of outpa-
tients with BD as HLA-B*51-negative cases after routine
HLA-typing. In all patients, BD was diagnosed according
to the International Criteria for BD (ICBD) [1]. The
Turkish (T) and German (G) BD patients presented with
the following clinical symptoms: oral aphthae (n (T/G) =
34/49), genital ulcers (n (T/G) = 8/25), erythema nodosum
(n (T/G) = 21/16), papulopustules (n (T/G) = 23/35), fol-
liculitis (n (T/G) = 1/5), arthritis (n (T/G) = 17/25), cerebral
attack (n (T/G) = 1/3), ocular manifestation (n (T/G) = 16/
25) and venous thrombosis (n (T/G) = 7/7). Local panels
of 1,500 healthy German and 130 Turkish individuals
negative for HLA-B*51 were used for comparison of
HLA-allele frequencies in both patient populations. Thestudy was approved by the Ethik-Kommission of the
Medical Faculty, University of Tübingen (project 225/
2007BO2). Blood samples were collected after written in-
formed consent of all participants for their enrollment.
HLA genotyping
Genomic DNA was isolated with the use of QIAamp
Blood Mini kits (Qiagen N.V. Hilden, Germany) from 5 ml
EDTA blood samples drawn from each patient, as well as
from the controls, after informed consent. HLA-A und -B
genotypes were determined by LUMINEX technology with
the use of the LABType (®) SSO typing kits (One Lambda,
Inc., Canoga Park, CA, USA). HLA Fusion™ Software Ver-
sion 2.0 (One Lambda Inc.) was used for data analysis.
Statistical analysis
Allele (determinant) frequencies were estimated by direct
counting. The 2 × 2 contingency tables for each individual
allele were used, where n refers to the number of alleles
detected in the population. The strength of the association
was estimated by an OR of risk and 95% CI. We used χ2-
analysis, P-values, and ORs with 95% CI for statistical
evaluation of HLA-allele differences between BD patients
and controls. The P-values (corrected P (Pc-value)) were
corrected by multiplying the number of observed alleles at
the locus. The significance level was set at Pc <0.05 for all
analyses. All P-values were derived from a two-sided test.
All statistical calculations were computed using the Epi
Info™ Version 7.0.8.3 (Clifton Rd, Atlanta, GA, USA). In
addition, two-locus haplotypes were generated by Arlequin
(v3.11) software using the allele status at the HLA-A and
B locus. The Bonferroni correction was applied to the
P-values [14,15].
Results
HLA-A associations in B*51 negative BD patients
To evaluate the influence of an HLA-A-linked second risk
locus, independently associated with BD of HLA-B*51,
distribution of HLA-A alleles was evaluated in BD. We an-
alyzed 65 German BD patients who were typed negative
for HLA-B*51 and compared them to 1,500 HLA-B*51-
negative healthy German controls (see Additional file 1:
Table S1). HLA-A*26 was significantly more frequent in
the German patients than in the respective healthy
controls (11 (16.9%) patients versus 89 (5.9%) healthy
Germans, Pc = 0.0076, OR = 3.23, 95% CI 1.63 to 6.39), as
it had been previously reported for Japanese [8], Taiwanese
[9] and Greek [10] patients. In addition, a tendency for a
negative association with HLA-A*03 was observed in the
German BD patients in comparison to the healthy control
group (11 (16.9%) patients versus 451 (30.1%) healthy
German controls, P = 0.022, Pc-value not significant, OR =
0.47, 95% CI 0.25 to 0.91). In contrast to other studies,
HLA-A*26 was also elevated in the HLA-B*51-negative
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healthy Turks, Pc = 0.019, OR = 15.73, 95% CI 1.78 to
138.56), however, significance should be confirmed in a
larger patient group. HLA-A*32 also showed a slight ele-
vation in the Turkish BD patients. No other significant
HLA-A differences were seen in German and Turkish BD
patients in comparison to the respective healthy controls.
HLA-B associations in B*51-negative BD patients
Elevated frequencies of various HLA-B locus alleles,
such as B*39, B*45, B*55 and B*57 (see Additional file 1:
Table S2), were observed in the German BD patients in
comparison to the controls. On the contrary, HLA-B*08
and HLA-B*40 alleles seemed to be negatively associated
with BD in Germans. In Turks, only HLA-B*57 was sig-
nificantly and consistently raised in the patient group. In
contrast, HLA-B*18 showed a tendency of a negative as-
sociation with BD in Turks.
These diverse HLA-B associations in HLA-B*51-nega-
tive German and Turkish patients as well as previous ex-
perimental hints for an involvement of NK cells in the
pathogenesis of BD raised the question, could HLA as a
ligand of NK cell receptors, in particular HLA-Bw4 as a
public determinant of HLA-B locus antigens, play a role in
genetic susceptibility to BD? In this regard, it was of inter-
est that HLA-B*51 strongly associated with BD belongs to
the HLA-B locus alleles coding for a Bw4 determinant
with isoleucine at amino acid position 80. Analysis of the
HLA-Bw4 determinant on HLA-B alleles showed only a
slight elevation in the German patient group in compari-
son to healthy controls (see Additional file 1: Table S3).
This was also seen for Bw4 as a determinant encoded by
some HLA-A alleles (A*23, A*24, A*25, A*32) or in a com-
bined analysis of Bw4-positive HLA-B and -A alleles (see
Additional file 1: Table S3). Bw4 homozygotes tended to
be increased, whereas Bw6 homozygotes seemed to be
slightly decreased in the German BD patients. Similar re-
sults were obtained for B*51-negative Turkish patients.
The Bw4 epitope is characterized by the NIALR sequence
motif of the polymorphic amino acid positions 77, 80 to 83
in the α1 helix of the HLA molecule [16]. Several studies
have shown that variant Bw4 HLA-B allotypes with isoleu-
cine or threonine at position 80 can be discriminated by
NK cells and manifest associations with different clinical
diseases. Analysis of these Bw4 HLA-B allotypes in the
B*51-negative BD patients revealed a significant associ-
ation of BD with presence of Bw4-80I, but not of Bw4-
80 T in the German groups (Bw4-80I P = 0.0007, Pc =
0.0042, OR = 2.35, 95% CI 1.41 to 3.93) (see Additional
file 1: Table S4). The same association was found in the
Turkish BD patient group, but with a significance level
not as robust as in the German patients after correction
for multiple testing. Interestingly, when we excluded all
BD patients carrying Bw4+ HLA-B alleles, an associationof BD to HLA-A*26 was no longer seen. Strong linkage
disequilibrium (LD) of HLA-A*26 with the HLA-Bw4-80I
allele B*49 (Dʹ=1.0; P = 0.001) (see Additional file 1:
Table S5) was observed in German patients, but not in
the respective controls. This indicated that the observed
HLA-A*26 association could be a result of LD with Bw4-
80I-positive HLA-B alleles. No significant specific LD of
HLA-A*26 with HLA-B alleles was observed in the
Turkish patients and healthy controls. When the HLA-
B*51-negative patient and control groups were stratified
for presence or absence of HLA-A*26, the association
of HLA-Bw4-80I with BD still held true in the German
patients (see Additional file 1: Table S6) Only a weak as-
sociation of HLA-Bw4-80I with BD was calculated from
a similar regression analysis of the Turkish cohorts.
Discussion
As in other ethnicities, HLA-B*51 has been previously
shown to be associated with BD in Germans, where this
disease rarely occurs in the native population. In this
study, new and additional HLA-linked associations were
discovered in German BD patients who were recruited as
HLA-B*51 non-carriers. First, HLA-A*26 was found to be
strongly associated with BD in Germans, as it had been
reported for Japanese [8], Greek [10] and Taiwanese [9]
cohorts. Additionally, our results clearly identified the
HLA-Bw4 epitope with isoleucine at position 80 as a pos-
sible major genetic susceptibility determinant of BD in
Germans. Comparative analysis of Turkish resident HLA-
B*51 non-carriers in Germany also indicated HLA-A*26
as a BD-associated susceptibility marker and showed a
significant, but less robust linkage with the HLA-Bw4-
80I epitope.
HLA-A*26 is one of the less frequent HLA-A alleles in
Germans, with a phenotype frequency of 5.9% in healthy
controls. It was clearly increased in the German patient
group lacking the HLA-B*51 allele with the strongest BD
association of all seen in the analyzed HLA alleles. This
finding, therefore, supports results of previous studies,
which suggested that the HLA-A*26 allele itself represents
an additional BD susceptibility gene independent of HLA-
B*51. LD analysis, however, indicated that the HLA-A*26
association could be a result of LD with the Bw4-80I-
positive HLA-B allele B*49 in German patients. The pheno-
type frequency of HLA-A*26 appeared to be also increased
in the Turkish patients, but not enough HLA-B*51 non-
carrier controls could be recruited to establish a statistically
safe association. So far, the role of HLA-A*26 in the patho-
genesis of BD still remains incompletely defined. HLA-
A*26 has been linked to acute Graft-versus-host disease
(GVHD) after allogeneic stem cell transplantation [17], to
lymphoproliferative disorders after solid organ grafts [18],
as well as to specific forms of psoriatic arthritis [19] as a
sign for a pathogenetic role also in other clinical diseases.
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molecules that bind with reduced affinity to the inhibitory
leucocyte immunoglobulin-like receptors (LILR) B1 on
myeloid cells, including dendritic cells, as well as on other
different immune cells that are involved in innate immunity
and inflammation [20,21]. Thus, for further insight into the
pathogenesis of BD, it could be of relevance to experimen-
tally clarify if such interactions influence the activity of pro-
fessional antigen-presenting cells, innate immune activation
or inflammation in BD. In this respect, HLA-A*03, which
on the contrary binds with stronger affinity than HLA-
A*26 to LILRB1 [20] and also ligates to the NK cell receptor
KIR3DL2 [22], could be of interest as a potential protective
allele with an observed negative association to BD and thus
should be investigated in further larger patient cohorts.
HLA-B locus alleles can be divided in two groups ac-
cording to their expression of the allelic determinants
Bw4 and Bw6 [23,24]. The Bw4 epitope with the com-
mon sequence NIALR at position 77 to 83 of the α1
helix of the HLA-B heavy chain has been shown to func-
tion as the binding site of the killer immunoglobulin-like
receptors (KIR) KIR3DL1 on NK cells, with influences
on NK and T-cell activation in innate and adaptive im-
mune responses [25]. So far, in several studies, abnor-
malities in circulating NK cells have been reported and
shown to correlate with disease activity or response to
therapy [26,27]. Therefore, we analyzed frequency of the
Bw4 epitope either expressed on HLA-A or HLA-B or
on allotypes of both loci in the German and Turkish pa-
tient groups of HLA-B*51 non-carriers. However, no sig-
nificant differences between BD patients and controls
were found in Germans and Turks. The HLA-Bw4 epi-
tope exists on HLA-B and some HLA-A proteins in at
least eight variant subtypes with differential binding ac-
tivity to KIR3DL1, in particular for the dimorphic Bw4
allotypes with either isoleucine (Bw4-80I) or threonine
(Bw4-80 T) at amino acid position 80 [16]. Interestingly,
for the first time we observed that the HLA-B/Bw4-80I,
but not the Bw4-80 T variant was significantly associated
with BD in a German and to a weaker statistical power
also in a Turkish patient cohort of HLA-B*51 non-
carriers. HLA-B*51, which was previously shown to be
strongly associated with BD also codes for the Bw4-80I
epitope. As such, the HLA-B*51 HLA-association of BD
does not contradict our hypothesis that HLA-Bw4-80I
could play a role in pathogenesis of the disease through
the control of NK-/T-cell interactions with myeloid cells
via ligation with KIR3DL allotypes. In a previous analysis
by Middleton et al. [28] no association between KIR
genes and BD in B*51-positive/negative or Bw4-positive/
negative patients had been observed. This supports our
observation that not all Bw4 determinants, but only
Bw4-80-I ligands might be associated with BD. KIR3DL1
is a highly polymorphic locus with alleles coding for NKcell inhibiting and activating molecules. According to
Norman et al. [29] all KIR3DL1 variants can be grouped
into one of three families with sequence variation at
specific amino acid positions maintained by balancing se-
lection through human evolution. DX9, a monoclonal
antibody against KIR3DL1 molecules appears to differenti-
ate the products of these three lineages [30]. In a recent
analysis, it was used to stain lymphocyte and NK cells in
BD, but did not detect differences in the expression of
KIR3DL1 in patients and controls [31]. Nevertheless, like
in other diseases with evidence of a pathogenic role of the
KIR3DL1/Bw4 interaction [32], it may also be relevant in
BD to precisely determine the specific KIR3DL1 subtypes
in order to detect mutual influences of NK cell receptors
together with Bw4-80I on the pathogenesis of the disease.
In addition, it has been shown that pathogen- or stress-
derived peptides presented by the HLA-B molecule could
alter the binding face of the Bw4 epitope for KIR inter-
action [33,34]. In this respect, it may be of interest to note
that the expression of the Bw4 epitope on granulocytes
significantly varied from the Bw4 epitope on lymphocytes
in BD patients, but not in controls (manuscript in prep-
aration). Since KIR expression is also found on different
T-cell subtypes, variant expression could also be critical
for disease development in cell types other than NK
cells, and it will thus be a challenge for future analysis
to identify effector and target cells with altered KIR/
Bw4 interaction in BD.
Conclusion
The study suggests for the first time that HLA-B*51 to-
gether with other HLA-Bw4-80I-positive HLA-B mole-
cules might play an important role as a T-cell as well as
an NK-cell ligand in the pathogenesis of BD. The ob-
served association of HLA-A*26 with BD, particularly in
the German patients, appeared to also depend on the
linkage to a Bw4-80I-positive HLA-B allele and thus, did
not unequivocally point to a second HLA-A-linked sus-
ceptibility locus of BD.
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